STI Stock Trade Intelligence
XEN

Xenitra Ltd

Consumer Discretionary · ASX:XEN
$0.0030
0.00%
Market cap
$12M
Turnover
$1,239
Last price
$0.0030
Day change
0.00%
Announcements
17
Range, past year
Open 0.003 · Low 0.002 · Now 0.003 · High 0.004
Open XEN in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.

XEN momentum and trend analysis

Our analysis
Independent analysis generated by Stock Trade Intelligence as at 2026-09-28.
Momentum quality
18/100
Wyckoff phase
Accumulation21d
Trend stage
Neutral
1 Day
+0.0%
1 Week
+50.0%
1 Month
-25.0%
RSI
53
Avg daily range
13.7%

Xenitra Ltd scores 18 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.

On the Wyckoff cycle it sits in Accumulation, where it has been for 21 trading days. The weekly timeframe reads Accumulation, which agrees with the daily view.

Against the wider market it is currently outperforming and the institutional accumulation signal reads low.

Points to watch
  • 60d drawdown -50.0%
  • High volatility (ATR 13.7%)
  • Thin liquidity
  • Risk rating: High
  • Composite downside risk elevated
XEN appears on this screen:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highs

XEN announcements

Recent price-sensitive releases.
  • 2026-08-31 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
  • 2026-08-24 Xenitra Raises $1.5m to Accelerate High-Margin Sales Growth Placement | Trading Halt Lifted
  • 2026-08-20 Trading Halt Trading Halt
  • 2026-08-18 $5m Offtake Agreement Expands OTC-Medicine Business Progress Report
  • 2026-07-30 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
  • 2026-07-27 $12M OFFTAKE AGREEMENT WITH LEADING OTC-PHARMACEUTICAL Progress Report
  • 2026-06-04 $1.1m in OPAL-Tokenised Product Sales in First 7 Weeks
Get the daily briefing The day's price-sensitive announcements, ranked by what actually moved, with our own momentum and cycle read on each.